Brasília – The president of international operations at Novartis, Patrick Horber, stated that conducting clinical trials in Brazil benefits patients, researchers, institutions and the pharmaceutical industry alike. In an interview, Horber highlighted that Brazil’s genetic diversity, qualified medical centers and improving regulatory environment make the country a strategic hub for global drug development.

According to the executive, patients gain early access to innovative treatments while companies obtain more representative data and strengthen their scientific collaboration with local hospitals and universities. He also underscored that such studies generate investment, capacity building and technology transfer, creating a virtuous cycle for innovation in health.

Horber emphasized that Brazil has consolidated its role as one of the key emerging markets for clinical research, especially in oncology and rare diseases, but noted that continued regulatory agility and investment in infrastructure are essential for the country to remain competitive.

Source: O Globo

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com